Lebrikizumab-Treated Patients With Atopic Dermatitis Had No Increase in Treatment-Emergent Adverse Events of Facial, Head, and Neck Erythema Compared to Placebo

Main Article Content

Jenny E. Murase
University of California, San Francisco, USA

Monica Munera-Campos
Hospital Universitari Germans Trias i Pujol, Barcelona, Spain

H. Chih-ho Hong
University of British Columbia, Vancouver, Canada

Alain Taieb
INSERM U 1312, University of Bordeaux, Bordeaux, France

Wen-Hung Chung
Chang Gung University, Taoyuan City, Taiwan

Amber Reck Atwater
Eli Lilly and Company, Indianapolis, USA

Maria Jose Rueda
Eli Lilly and Company, Indianapolis, USA

Jinglin Zhong
IQVIA, Durham, USA

Maria Lucia Buziqui Piruzeli
Eli Lilly and Company, Indianapolis, USA

Ignasi Pau-Charles
Almirall S.A., Barcelona, Spain

Mette Deleuran
Aarhus University Hospital, Aarhus, Denmark

Keywords

Lebrikizumab, atopic dermatitis, erythema

References

1. Kozera E, et al. Br J Dermatol. 2022;186:1050-1052.

2. Uchida H, et al. J Eur Acad Dermatol Venereol. 2023;37:e300-e302.

3. Okragly AJ, et al. Dermatol Ther (Heidelb). 2023;13:1535-1547.

4. Guttman-Yassky E, et al. JAMA Dermatol. 2020;156:411-420.

5. Silverberg JI, et al. N Engl J Med. 2023;388:1080-1091.

6. Simpson EL, et al. JAMA Dermatol. 2023;159:182-191.

7. Paller AS, et al. Dermatol Ther (Heidelb). 2023;13:1517-1534.

8. Stein Gold L, et al. Am J Clin Dermatol. 2023;24:595-607.

Article Sidebar

PDF
Published
Nov 13, 2023
DOI https://doi.org/10.25251/skin.7.supp.272

Article Details

How to Cite
[1]
Murase, J.E. , Munera-Campos, M. , Hong, H.C.- ho ., Taieb, A. , Chung, W.-H. , Reck Atwater, A., Rueda, M.J. , Zhong, J. , Buziqui Piruzeli, M.L. , Pau-Charles, I. and Deleuran, M. 2023. Lebrikizumab-Treated Patients With Atopic Dermatitis Had No Increase in Treatment-Emergent Adverse Events of Facial, Head, and Neck Erythema Compared to Placebo. SKIN The Journal of Cutaneous Medicine. 7, 6 (Nov. 2023), s272. DOI:https://doi.org/10.25251/skin.7.supp.272.
Issue
Vol. 7 No. 6 (2023): November 2023 Issue
Section
Atopic Dermatitis
Creative Commons License

This work is licensed under a Creative Commons Attribution 4.0 International License.

All authors retain copyright in their articles. All articles published open access allowing for immediate free access to the work and permitting any user to read, download, copy, distribute, print, search, or link to the full texts of articles, crawl them for indexing, pass them as data to software or use them for any other lawful purpose. Permitted reuse is defined by  the following user license:
 

Creative Commons Attribution (CC BY): lets others distribute and copy the article, to create extracts, abstracts, and other revised versions, adaptations or derivative works of or from an article (such as a translation), to include in a collective work (such as an anthology), to text or data mine the article, even for commercial purposes, as long as they credit the author(s), do not represent the author as endorsing their adaptation of the article, and do not modify the article in such a way as to damage the author's honor or reputation. 

Authors retain copyright in their work and license the publisher to publish the content. The publisher is the National Society for Cutaneous Medicine, with production and publishing support provided by OJS, Open Journal Systems,see https://pkp.sfu.ca/ojs/.

Prior to January 2022, authors transferred copyright to the National Society for Cutaneous Medicine. However, all articles are freely available to anyone in the world. There are no subscription fees, page charges, or article processing charges.

Similar Articles

You may also start an advanced similarity search for this article.

Most read articles by the same author(s)

1 2 > >>